Business

Development of novel antibiotics

Therapeutic Focus

Severe infections

Pipeline

• Oxaquin, novel antibiotic with unique mode of action, in phase I clinical trials
• Topoisomerase Inhibitors, novel class of antibiotic compounds, start of clinical trials anticipated for 2008

Team

Executive management:

• Erich Felber, MD, MBA; Chief Executive Officer
• Thomas Kapsner, MD; Chief Operating Officer
• Gertraud Unterrainer, PhD; VP Finance
• Thomas Gramatté, MD; VP Medical Affairs and Clinical Development

Finance

€ 21 million in equity and silent partnership investments from TVM Capital, Life Sciences Partners (LSP) and Kapital und Wert